CD47 and neoplasm: Bioluminescence imaging data showed a significantly decreased tumor burden in mice treated with doxorubicin plus CD47 mAb as compared to mice treated with doxorubicin only (P = 0.01), CD47 mAb only (P = 0.03), or control IgG (P = 0.001, Fig. 4A,B).